Prognostic Value of Pretreatment Serum Cystatin C Level in Nasopharyngeal Carcinoma Patients in the Intensity-modulated Radiotherapy Era

Tan, Xiao-Ying; Huang, Shao Min; Gong, Sha; Chen, Yang; Yang, Xiaojing; He, Qing‐Mei; He, Shiwei; Liu, Na; Li, Ying-Qing

doi:10.2147/ott.s286009

Cited by 1 publication

(2 citation statements)

References 43 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Cys C is unrelated to gender, diet, or body surface area and is synthesized and released uniformly inside the blood, rendering it an ideal laboratory marker. 17,18 Cys C is a sensitive laboratory index used to assess renal function and could be linked with neurological diseases. Thus, detecting Cys C levels in specific tissues and body fluids is significant in identifying disease markers and studying disease progression and treatment effects.…”

Section: Introductionmentioning

confidence: 99%

“…Serum Cys C, a cysteine protease inhibitor C synthesized by nucleated cells, widely exists in all body fluids. However, Cys C is unrelated to gender, diet, or body surface area and is synthesized and released uniformly inside the blood, rendering it an ideal laboratory marker 17,18 . Cys C is a sensitive laboratory index used to assess renal function and could be linked with neurological diseases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The severity assessment of Parkinson's disease based on plasma inflammatory factors and third ventricle width by transcranial sonography

Lu,

Dong,

Xue

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

BackgroundPredicting Parkinson's disease (PD) can provide patients with targeted therapies. However, disease severity can be roughly evaluated in clinical practice based on the patient's symptoms and signs.ObjectiveThe current study attempted to explore the factors linked with PD severity and construct a predictive model.MethodThe PD patients and healthy controls were recruited from our study center while recording their basic demographic information. The serum inflammatory markers levels, such as Cystatin C (Cys C), C‐reactive protein (CRP), RANTES (regulated on activation, normal T cell expressed and secreted), Interleukin‐10 (IL‐10), and Interleukin‐6 (IL‐6) were determined for all the participants. PD patients were categorized into early and mid‐advanced groups based on the Hoehn and Yahr (H‐Y) scale and evaluated using PD‐related scales. LASSO logistic regression analysis (Model C) helped select variables based on clinical scale evaluations, serum inflammatory factor levels, and transcranial sonography measurements. The optimal harmonious model coefficient λ was determined via 10‐fold cross‐validation. Moreover, Model C was compared with multivariate (Model A) and stepwise (Model B) logistic regression. The area under the curve (AUC) of a receiver operator characteristic (ROC), brier score, calibration curve, and decision curve analysis (DCA) helped determine the discrimination and calibration of the predictive model, followed by configuring a forest plot and column chart.ResultsThe study included 113 healthy individuals and 102 PD patients, with 26 early and 76 mid‐advanced patients. Univariate analysis of variance screened out statistically significant differences among inflammatory markers Cys C and RANTES. The average Cys C level in the mid‐advanced stage was significantly higher than in the early stage (p < 0.001) but not for RANTES (p = 0.740). The LASSO logistic regression model (λ.1se = 0.061) associated with UPDRS‐I, UPDRS‐II, UPDRS‐III, HAMA, PDQ‐39, and Cys C as the included independent variables revealed that the Model C discrimination and calibration (AUC = 0.968, Brier = 0.049) were superior to Model A (AUC = 0.926, Brier = 0.079) and Model B (AUC = 0.929, Brier = 0.071) models.ConclusionThe study results show multiple factors are linked with PD assessment. Moreover, the inflammatory marker Cys C and transcranial sonography measurement could objectively predict PD symptom severity, helping doctors monitor PD evolution in patients while targeting interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%